OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
-4.64%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$606M
AUM Growth
+$606M
(-26%)
Cap. Flow
-$244M
Cap. Flow
% of AUM
-40.22%
Top 10 Holdings %
Top 10 Hldgs %
67.2%
Holding
58
New
2
Increased
13
Reduced
12
Closed
14
Top Buys
| 1 |
Structure Therapeutics
GPCR
|
$24.9M |
| 2 |
Dianthus Therapeutics
DNTH
|
$9.47M |
| 3 |
RGLS
Regulus Therapeutics
RGLS
|
$7.61M |
| 4 |
Terns Pharmaceuticals
TERN
|
$5.04M |
| 5 |
AN2 Therapeutics
ANTX
|
$4.55M |
Top Sells
| 1 |
Perspective Therapeutics
CATX
|
$131M |
| 2 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$49.2M |
| 3 |
Insmed
INSM
|
$32.8M |
| 4 |
Cytokinetics
CYTK
|
$13.6M |
| 5 |
NewAmsterdam Pharma
NAMS
|
$9.65M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $111M | 17.37% | 2,880,880 +73,900 | +3% | +$2.83M |
|
|
2
Dianthus Therapeutics
DNTH
$759M
| $45.2M | 7.1% | 1,746,667 +366,000 | +27% | +$9.47M |
|
|
3
Structure Therapeutics
GPCR
$1.11B
| $44.8M | 7.04% | 1,140,060 +633,456 | +125% | +$24.9M |
|
|
4
Insmed
INSM
$28.8B
| $43.6M | 6.85% | 650,216 -489,784 | -43% | -$32.8M |
|
5
Dyne Therapeutics
DYN
$1.92B
| $41.7M | 6.55% | 1,180,798 -62,147 | -5% | -$2.19M |
|
6
ArriVent BioPharma
AVBP
$776M
| $33.5M | 5.26% | 1,803,304 -140,532 | -7% | -$2.61M |
|
|
VRNA
7
Verona Pharma
VRNA
$9.16B
| $27.4M | 4.31% | 1,895,200 -473,800 | -20% | -$6.85M |
|
8
Corbus Pharmaceuticals
CRBP
$115M
| $22.1M | 3.47% | 488,000 +83,000 | +20% | +$3.76M |
|
|
CNTA
9
Centessa Pharmaceuticals
CNTA
$2.25B
| $21.2M | 3.33% | 2,345,075 +284,975 | +14% | +$2.57M |
|
10
BridgeBio Pharma
BBIO
$9.89B
| $17.5M | 2.75% | 690,000 | – | – |
|
11
Ocular Therapeutix
OCUL
$2.12B
| $16.6M | 2.61% | 2,425,000 | – | – |
|
|
12
Perspective Therapeutics
CATX
$250M
| $15.8M | 2.48% | 1,580,249 -13,138,173 | -89% | -$131M |
|
13
MindMed
MNMD
$676M
| $15.5M | 2.44% | 2,153,000 | – | – |
|
14
Praxis Precision Medicines
PRAX
$958M
| $10.8M | 1.69% | 260,000 | – | – |
|
15
Taysha Gene Therapies
TSHA
$797M
| $10.2M | 1.61% | 4,572,222 +1,542,222 | +51% | +$3.45M |
|
16
EyePoint Pharmaceuticals
EYPT
$797M
| $9.51M | 1.5% | 1,093,503 | – | – |
|
|
17
Terns Pharmaceuticals
TERN
$609M
| $9.29M | 1.46% | 1,364,400 +739,400 | +118% | +$5.04M |
|
18
Gossamer Bio
GOSS
$562M
| $8.28M | 1.3% | 9,187,883 | – | – |
|
19
Viridian Therapeutics
VRDN
$1.5B
| $8.07M | 1.27% | 620,000 | – | – |
|
20
Tenaya Therapeutics
TNYA
$184M
| $7.99M | 1.26% | 2,576,200 -277,800 | -10% | -$861K |
|
|
RGLS
21
DELISTED
Regulus Therapeutics
RGLS
| $7.61M | 1.2% | +4,263,701 | New | +$7.61M |
|
|
KLRS
22
Kalaris Therapeutics, Inc. Common Stock
KLRS
$76.3M
| $7.09M | 1.11% | 9,800,000 +5,600,000 | +133% | +$4.05M |
|
23
Mineralys Therapeutics
MLYS
$1.03B
| $7.02M | 1.1% | 600,000 +50,000 | +9% | +$585K |
|
|
24
AN2 Therapeutics
ANTX
$30.1M
| $6.92M | 1.09% | 3,220,263 +2,117,263 | +192% | +$4.55M |
|
25
Akero Therapeutics
AKRO
$3.74B
| $6.65M | 1.04% | 283,372 -56,628 | -17% | -$1.33M |
|